AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

Elizabeth Cairns

Senior biopharma journalist

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for Alexion in 2021. The UK major recorded …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires Novartis oncology exec to steer its cancer ambitions

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

Bristol Myers prunes pipeline amid new round of cost cuts

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

AstraZeneca offers some detail on China probe, reaffirms commitment to that market

As­traZeneca takes $753M charge on aban­doned com­ple­ment drug from Alex­ion deal

Senior biopharma journalist

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal